The CD147 Expression in CD4+ T Cells is a Novel Biomarker for Predicting Efficacy of IL-17A Inhibitor and Psoriasis Recurrence.
Panpan Liu,Lei Li,Yehong Kuang,Wu Zhu,Jie Li,Xiang Chen,Cong Peng
DOI: https://doi.org/10.1002/ctm2.1568
IF: 8.554
2024-01-01
Clinical and Translational Medicine
Abstract:Here, we demonstrated the crucial functions of CD147 expressed by CD4+ T cells in the pathogenesis and recurrence of psoriasis and developed two novel predictive models that accurately predict the therapeutic effect and durable efficacy of IL-17A inhibitor, providing an understanding of psoriasis pathogenesis and implications for personalised treatment approaches in psoriasis therapy. Although significant progress had been made in the treatment of psoriasis, the lack of effective biomarkers for predicting treatment efficacy and psoriasis recurrence remains a big challenge.1, 2 CD147 is a transmembrane glycoprotein that was reported to be highly expressed in psoriatic lesions.3 However, the role of CD147 expressed by CD4+ T cells in the progression of psoriasis remains uncertain. We found after IL-17A inhibitor treatment, psoriasis patients with a psoriasis area and severity index (PASI) 75 response showed an elevated CD147 expression on CD4+ T cells (Table S1 and Figures 1A and S1A,B). However, psoriasis patients without a PASI75 response showed a decreased CD147 expression on CD4+ T cells (Table S1 and Figures 1B and S1C). The improvements in the PASI score were positively correlated with the changes in the CD147 expression of psoriasis patients following IL-17A inhibitor therapy (Figure 1C), whereas negatively associated with the CD147 expression of psoriasis patients before treatment (Figure 1D). Furthermore, following 4 weeks of IL-17A inhibitor treatment or after 1 year of withdrawal, psoriasis patients with recurrence showed less variation in CD147 expression on the CD4+ T cells than those without recurrence (Figure 1E,F and Table S2). Two innovative predictive models had been developed based on the discovery of elevated CD147 expression by CD4+ T cells of psoriasis patients who showed positive treatment response and sustained remission. These models effectively forecast the therapeutic efficacy (Figures 1G and S2A–D and Tables S3 and S4) and long-term effectiveness of IL-17A inhibitors for treating psoriasis (Figures 1H and S2E–H and Tables S5 and S6). Researchers found that lipopolysaccharide-induced NF-κBp65 phosphorylation was a predictive biomarker of nonresponse to adalimumab.4 Here, we developed two easy-to-apply models with the decent predictive capability, which provided suggestions for individualised treatment plans and patient education. Considering the limitations of the study, multicentre studies and external validation were needed to improve the prediction model. To investigate the role of CD147 in psoriasis, CD4+ T-cell-specific CD147-knockout mice (CD4creBsgfl/fl) was developed to establish the psoriasis-like model. We found genomic knock out CD147 in CD4+ T cells aggravated the pathogenesis of psoriasis (Figures 2A, S3A–D and S4A–E). The number of Th17 and Th1 cells in skin lesions of CD4creBsgfl/fl group was notably elevated when compared to Bsgfl/fl group (Figures 2B,C, S3E–H and S4F–I). Skin-resident memory T cells (TRM) are crucial for preserving immunological memory and mediating rapid immune responses against recurring pathogens. TRM cells express CD69 or CD103,5 and contribute to the chronic inflammation by continuously producing proinflammatory cytokines, such as IL-17A.6 We found genomic knock out CD147 in CD4+ T cells accelerated the recurrence progression of psoriasis (Figures 2D, S5 and S6). We noted that during the acute stage, the number of CD4+CD103+ TRM cells increased in CD4creBsgfl/fl mice with higher expression of IL-17A (Figures 2E–H and S7A,B). Nevertheless, there was no notable difference in the quantity of TRM cells and its IL-17A expression in the CD4creBsgfl/fl and Bsgfl/fl groups during the resolved stage (Figures 2E–H and S7C,D). During the recurrence stage, the number of CD4+CD69+ and CD4+CD103+ TRM cells and its IL-17A expression were notable elevated in CD4creBsgfl/fl mice compared with Bsgfl/fl mice (Figures 2E–H and S7E,F). Taken together, CD147 deficiency increased the number of TRM cells in skin lesions with a higher IL-17A expression, accelerating the recurrence of psoriasis. In psoriasis, the expression of CD147 was negatively corelated to the IL-17A expression in CD4+ T cells (Figures 3A and S8A,B and Table S1). We then explored the function of CD147 on the differentiation of Th17 cells. The findings showed that CD147 deficiency promoted the differentiation of pathogenic Th17 cells (Figures 3B and S8C). RNA sequencing indicated that the impact of CD147 on the polarisation of Th17 cells involves the cytokine–receptor interaction pathway, such as IL-6–STAT3 signalling pathways (Figure S8D). And we found CD147 effectively inhibited the activation of p-JAK2 and p-STAT3 in CD4+ T cells (Figures 3C and S8E,F), which is the key transcription factor of IL-17A.7 Since CD147 could modify intracellular signalling by interacting with various proteins,8 we tested the interaction between CD147 and IL-6R and showed that CD147 deficiency in CD4+ T cells enhanced the IL-6R expression (Figures 3D,E and S8G). The endogenous and exogenous immunoprecipitations revealed that CD147 could interact with IL-6R (Figures 3F,G and S8H). Confocal immunofluorescence showed that CD147 interacted with IL-6R on the membrane of CD4+ T cells before the stimulation with IL-6. When IL-6 was applied, the CD147–IL-6R complex was endocytosed into the lysosome (Figure 3H). Therefore, CD147 promoted the endocytosis of IL-6R and then inhibited Th17 differentiation. The retention of TRM cells was dependent on the IL-15R expression on the membrane.9 Thus, we investigated whether there was an interaction between CD147 and IL-15R. The findings indicated that IL-15R protein expression was notably reduced on Bsgfl/fl CD4+ T cells, while no notable variation in the IL-15R mRNA expression was found in CD4creBsgfl/fl and Bsgfl/fl CD4+ T cells, both before and after IL-15 stimulation (Figure 4A–C). We further showed that CD147 interacted with IL-15R in CD4+ T cells by endogenous immunoprecipitation (Figure 4D,E). Confocal immunofluorescence revealed that CD147 interacted with IL-15R on the membrane of CD4+ T cells. Following the IL-15 simulation, the CD147–IL-15R complex was endocytosed into the lysosome (Figure 4F). In addition, CD147 deficiency promoted the expression of IL-17A in TRM cells (Figure 4G). In summary, we found CD147 expression by CD4+ T cells was correlated with the treatment efficacy and recurrence of psoriasis. CD147 expression by CD4+ T cells may serve as a predictive marker for the efficacy and recurrence of IL-17A inhibitors treatment of psoriasis. Moreover, CD147 plays a protective function in the development and recurrence of psoriasis by inhibiting the Th17 differentiation and the retention of TRM cells (Figure 4H). Panpan Liu, Xiang Chen and Cong Peng conceived the project and wrote the manuscript. Panpan Liu designed, performed experiments, and analysed the data. Lei Li, Yehong Kuang, and Jie Li helped with mouse experiments. Wu Zhu, Yehong Kuang, and Jie Li diagnosed with plaque psoriasis and provided patient samples and information. Panpan Liu and Cong Peng edited the manuscript. Xiang Chen and Cong Peng supervised the work. This work was supported by the National Natural Science (grant nos. 82073458, 81830096, 82173424, 82221002, 82130090, 81974476, and 82302707), the Science and Technology Innovation Program of Hunan Province (2021RC4013), the Program of Introducing Talents of Discipline to Universities (111 Project, no. B20017), the Changsha Natural Science Foundation (kq2208388), and the China Postdoctoral Science Foundation (2023M743948). The authors declare they have no conflicts of interest. The study was approved by the Ethics Committees of Xiangya Hospital (2019030227 and 202103587). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.